Treatment Adherence Among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa

Success in multidrug-resistant tuberculosis (MDR-TB) and HIV treatment requires high medication adherence despite high pill burdens, frequent adverse events, and long treatment duration, which may jeopardize adherence. We prospectively compared MDR-TB/HIV-coinfected persons to those with MDR-TB alon...

Full description

Saved in:
Bibliographic Details
Published in:Journal of acquired immune deficiency syndromes (1999) Vol. 82; no. 2; p. 124
Main Authors: Stephens, Fay, Gandhi, Neel R, Brust, James C M, Mlisana, Koleka, Moodley, Pravi, Allana, Salim, Campbell, Angie, Shah, Sarita
Format: Journal Article
Language:English
Published: United States 01.10.2019
Subjects:
ISSN:1944-7884, 1944-7884
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Success in multidrug-resistant tuberculosis (MDR-TB) and HIV treatment requires high medication adherence despite high pill burdens, frequent adverse events, and long treatment duration, which may jeopardize adherence. We prospectively compared MDR-TB/HIV-coinfected persons to those with MDR-TB alone to determine the impact of concurrent treatment on adherence and outcomes. We assessed medication adherence monthly using 3-day recall, 30-day recall, and visual analog scale and examined adherence to monthly study visits (months 0-12). We determined the proportion of participants fully adherent (no reported missed doses) to MDR-TB vs. HIV treatment by each measure. We assessed the association of medication and clinic visit adherence with MDR-TB treatment success (cure or completion, 18-24 months) and HIV virologic suppression. Among 200 patients with MDR-TB, 63% were women, median age was 33 years, 144 (72%) were HIV-infected, and 81% were receiving antiretroviral therapy (ART) at baseline. Adherence to medications (81%-98% fully adherent across all measures) and clinic visits (80% missed ≤1 visit) was high, irrespective of HIV status. Adherence to ART was significantly higher than to MDR-TB treatment by all self-reported measures (3-day recall: 92% vs. 84%, respectively; P = 0.003). In multivariable analysis, the adjusted risk ratio of unsuccessful MDR-TB treatment increased with every missed visit: 1.50, 2.25, and 3.37 for unsuccessful treatment, for 1, 2, and ≥3 missed visits. Adherence to ART was higher than to MDR-TB treatment among persons with MDR-TB/HIV coinfection. Missed clinic visits may be a simple measure for identifying patients at risk of unsuccessful MDR-TB treatment outcome.
AbstractList Success in multidrug-resistant tuberculosis (MDR-TB) and HIV treatment requires high medication adherence despite high pill burdens, frequent adverse events, and long treatment duration, which may jeopardize adherence. We prospectively compared MDR-TB/HIV-coinfected persons to those with MDR-TB alone to determine the impact of concurrent treatment on adherence and outcomes. We assessed medication adherence monthly using 3-day recall, 30-day recall, and visual analog scale and examined adherence to monthly study visits (months 0-12). We determined the proportion of participants fully adherent (no reported missed doses) to MDR-TB vs. HIV treatment by each measure. We assessed the association of medication and clinic visit adherence with MDR-TB treatment success (cure or completion, 18-24 months) and HIV virologic suppression. Among 200 patients with MDR-TB, 63% were women, median age was 33 years, 144 (72%) were HIV-infected, and 81% were receiving antiretroviral therapy (ART) at baseline. Adherence to medications (81%-98% fully adherent across all measures) and clinic visits (80% missed ≤1 visit) was high, irrespective of HIV status. Adherence to ART was significantly higher than to MDR-TB treatment by all self-reported measures (3-day recall: 92% vs. 84%, respectively; P = 0.003). In multivariable analysis, the adjusted risk ratio of unsuccessful MDR-TB treatment increased with every missed visit: 1.50, 2.25, and 3.37 for unsuccessful treatment, for 1, 2, and ≥3 missed visits. Adherence to ART was higher than to MDR-TB treatment among persons with MDR-TB/HIV coinfection. Missed clinic visits may be a simple measure for identifying patients at risk of unsuccessful MDR-TB treatment outcome.
Success in multidrug-resistant tuberculosis (MDR-TB) and HIV treatment requires high medication adherence despite high pill burdens, frequent adverse events, and long treatment duration, which may jeopardize adherence. We prospectively compared MDR-TB/HIV-coinfected persons to those with MDR-TB alone to determine the impact of concurrent treatment on adherence and outcomes.BACKGROUNDSuccess in multidrug-resistant tuberculosis (MDR-TB) and HIV treatment requires high medication adherence despite high pill burdens, frequent adverse events, and long treatment duration, which may jeopardize adherence. We prospectively compared MDR-TB/HIV-coinfected persons to those with MDR-TB alone to determine the impact of concurrent treatment on adherence and outcomes.We assessed medication adherence monthly using 3-day recall, 30-day recall, and visual analog scale and examined adherence to monthly study visits (months 0-12). We determined the proportion of participants fully adherent (no reported missed doses) to MDR-TB vs. HIV treatment by each measure. We assessed the association of medication and clinic visit adherence with MDR-TB treatment success (cure or completion, 18-24 months) and HIV virologic suppression.METHODSWe assessed medication adherence monthly using 3-day recall, 30-day recall, and visual analog scale and examined adherence to monthly study visits (months 0-12). We determined the proportion of participants fully adherent (no reported missed doses) to MDR-TB vs. HIV treatment by each measure. We assessed the association of medication and clinic visit adherence with MDR-TB treatment success (cure or completion, 18-24 months) and HIV virologic suppression.Among 200 patients with MDR-TB, 63% were women, median age was 33 years, 144 (72%) were HIV-infected, and 81% were receiving antiretroviral therapy (ART) at baseline. Adherence to medications (81%-98% fully adherent across all measures) and clinic visits (80% missed ≤1 visit) was high, irrespective of HIV status. Adherence to ART was significantly higher than to MDR-TB treatment by all self-reported measures (3-day recall: 92% vs. 84%, respectively; P = 0.003). In multivariable analysis, the adjusted risk ratio of unsuccessful MDR-TB treatment increased with every missed visit: 1.50, 2.25, and 3.37 for unsuccessful treatment, for 1, 2, and ≥3 missed visits.RESULTSAmong 200 patients with MDR-TB, 63% were women, median age was 33 years, 144 (72%) were HIV-infected, and 81% were receiving antiretroviral therapy (ART) at baseline. Adherence to medications (81%-98% fully adherent across all measures) and clinic visits (80% missed ≤1 visit) was high, irrespective of HIV status. Adherence to ART was significantly higher than to MDR-TB treatment by all self-reported measures (3-day recall: 92% vs. 84%, respectively; P = 0.003). In multivariable analysis, the adjusted risk ratio of unsuccessful MDR-TB treatment increased with every missed visit: 1.50, 2.25, and 3.37 for unsuccessful treatment, for 1, 2, and ≥3 missed visits.Adherence to ART was higher than to MDR-TB treatment among persons with MDR-TB/HIV coinfection. Missed clinic visits may be a simple measure for identifying patients at risk of unsuccessful MDR-TB treatment outcome.CONCLUSIONSAdherence to ART was higher than to MDR-TB treatment among persons with MDR-TB/HIV coinfection. Missed clinic visits may be a simple measure for identifying patients at risk of unsuccessful MDR-TB treatment outcome.
Author Moodley, Pravi
Mlisana, Koleka
Allana, Salim
Shah, Sarita
Gandhi, Neel R
Stephens, Fay
Brust, James C M
Campbell, Angie
Author_xml – sequence: 1
  givenname: Fay
  surname: Stephens
  fullname: Stephens, Fay
  organization: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
– sequence: 2
  givenname: Neel R
  surname: Gandhi
  fullname: Gandhi, Neel R
  organization: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
– sequence: 3
  givenname: James C M
  surname: Brust
  fullname: Brust, James C M
  organization: Divisions of General Internal Medicine & Infectious Diseases, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY
– sequence: 4
  givenname: Koleka
  surname: Mlisana
  fullname: Mlisana, Koleka
  organization: Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa
– sequence: 5
  givenname: Pravi
  surname: Moodley
  fullname: Moodley, Pravi
  organization: Department of Virology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa
– sequence: 6
  givenname: Salim
  surname: Allana
  fullname: Allana, Salim
  organization: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
– sequence: 7
  givenname: Angie
  surname: Campbell
  fullname: Campbell, Angie
  organization: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
– sequence: 8
  givenname: Sarita
  surname: Shah
  fullname: Shah, Sarita
  organization: Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31513073$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtOwzAQRS1URB_wBwh5yYKUOLYbZxlVQCvKqxQWbCLXnrRBiVPsGMQf8NmkAkRnM6Ojo6uZ6aOOqQ0gdEzCIQmT-PwhnQ7DnYpIFO6hHkkYC2IhWGdn7qK-c69hSEaMJQeoSwknNIxpD30tLMimAtPgVK_BglGA06o2K3wP1tXG4TkoKN6Lloxro7y1W_nGl02hrV8Fc3CFa2TLFn4JVvmybgGWRuPJ9Bn_5xcGX3_IF1_64FY2sjzDj7Vv1jjNbaHkIdrPZeng6LcP0NPlxWI8CWZ3V9NxOgsUi0Y04FwqKkTOaXtAznVOBQWahHFOFB_FCdWEa7LUSsWxVLkkOWPt_kyI1haSRAN0-pO7sfWbB9dkVeEUlKU0UHuXRZFIeMwjtlVPflW_rEBnG1tU0n5mf9-LvgFQSnXG
CitedBy_id crossref_primary_10_3390_life11060528
crossref_primary_10_1177_00185787231224065
crossref_primary_10_36303_SAGP_1204
crossref_primary_10_1093_cid_ciae145
crossref_primary_10_3390_jcm9113575
crossref_primary_10_1007_s00203_025_04415_y
crossref_primary_10_1016_j_ijregi_2025_100647
crossref_primary_10_1183_13993003_00837_2020
crossref_primary_10_1097_JNC_0000000000000242
crossref_primary_10_21292_2075_1230_2022_100_11_56_65
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1097/QAI.0000000000002120
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1944-7884
ExternalDocumentID 31513073
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: K23 AI083088
– fundername: NIAID NIH HHS
  grantid: P30 AI050409
– fundername: NIAID NIH HHS
  grantid: R01 AI089349
– fundername: NCATS NIH HHS
  grantid: UL1 TR000454
– fundername: NCATS NIH HHS
  grantid: UL1 TR001073
– fundername: NIAID NIH HHS
  grantid: P30 AI124414
– fundername: NIAID NIH HHS
  grantid: R01 AI114304
– fundername: NIAID NIH HHS
  grantid: R01 AI087465
– fundername: NIAID NIH HHS
  grantid: K24 AI114444
– fundername: NIAID NIH HHS
  grantid: U19 AI111211
GroupedDBID ---
.-D
.XZ
.Z2
01R
0R~
1J1
354
40H
4Q1
4Q2
4Q3
5GY
5RE
5VS
77Y
7O~
8L-
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAQKA
AARTV
AASCR
AASOK
AASXQ
AAXQO
ABASU
ABBUW
ABDIG
ABIVO
ABVCZ
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACIJW
ACILI
ACLDA
ACOAL
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ADGGA
ADHPY
AE3
AE6
AEBDS
AFDTB
AFEXH
AFRAH
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BKOMP
BOYCO
BQLVK
BYPQX
C45
CGR
CS3
CUY
CVF
DIWNM
E.X
EBS
ECM
EEVPB
EIF
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRJ
FRP
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JK3
JK8
K8S
KD2
KMI
L-C
NPM
N~7
N~B
O9-
OAG
OAH
ODA
ODMTH
OHH
OHYEH
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OWV
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
RIG
RLZ
RXW
S4R
S4S
TAE
TEORI
TSPGW
V2I
VVN
W2D
W3M
WOQ
WOW
X3V
X3W
XYM
YOC
7X8
ABPXF
ABXYN
ABZZY
ACZKN
ADKSD
ADSXY
AFBFQ
AFNMH
AHQVU
AOQMC
ID FETCH-LOGICAL-c4263-55ac388f53130f5df383e3907f1c56793d15d1bdcc77acfa1f44ece4880f58a12
IEDL.DBID 7X8
ISICitedReferencesCount 11
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000509681700013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1944-7884
IngestDate Mon Sep 08 05:47:39 EDT 2025
Wed Feb 19 02:30:43 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4263-55ac388f53130f5df383e3907f1c56793d15d1bdcc77acfa1f44ece4880f58a12
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/6760842
PMID 31513073
PQID 2289575241
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2289575241
pubmed_primary_31513073
PublicationCentury 2000
PublicationDate 2019-10-01
20191001
PublicationDateYYYYMMDD 2019-10-01
PublicationDate_xml – month: 10
  year: 2019
  text: 2019-10-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of acquired immune deficiency syndromes (1999)
PublicationTitleAlternate J Acquir Immune Defic Syndr
PublicationYear 2019
SSID ssj0016449
Score 2.3630743
Snippet Success in multidrug-resistant tuberculosis (MDR-TB) and HIV treatment requires high medication adherence despite high pill burdens, frequent adverse events,...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 124
SubjectTerms Adult
Female
HIV Infections - drug therapy
Humans
Male
Middle Aged
Self Report
Treatment Adherence and Compliance
Tuberculosis, Multidrug-Resistant - drug therapy
Title Treatment Adherence Among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa
URI https://www.ncbi.nlm.nih.gov/pubmed/31513073
https://www.proquest.com/docview/2289575241
Volume 82
WOSCitedRecordID wos000509681700013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3Ivho2dqkNn2SMhwbujJljuFLSXPRwWjnavUv-LM96YU9CYJ96EOgIaQnJ9-5fghdtR3ue8ZrE5v2j1RwZhkeSItSXzEmbcELSpbxgxeGbDLxh5XDLavSKmudWChqmQrjI285YBnAJHDh3M7fLcMaZaKrFYXGKmoQgDJGqr3JMooAd71fRJUpNVlztC6d873WY9AvWxdWD2jw9u8gs7hsutv_XeYO2qpgJg5KudhFKyrZQxuDKpC-j75HdYI5DuRbWfKHA0M8hIcFBs8wAEo1Ne4G3EkTUbZxwkW9rlzkr9aTygz0hLFRHquFyGcpDGCeSNzrj_Fy_mmC77_4Sz7LrdD4iq5xQduHS4aiA_TcvRt1elZFymAJ09vdcl0uCGMazi5pa1dqMHEVARNb28K9gdMubVfasRTC87jQ3NaUwnqNntAu47ZziNaSNFHHCAMyaHtg0hApCJWMxRLgkCMI4QD8RMyb6LLe4wiE3kQyeKLSPIuWu9xER-WPiuZld46IAIYxiuvkD1-fok0AQH6ZnHeGGhqOvDpH6-LzY5otLgppgnc4HPwAO2bT0A
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+Adherence+Among+Persons+Receiving+Concurrent+Multidrug-Resistant+Tuberculosis+and+HIV+Treatment+in+KwaZulu-Natal%2C+South+Africa&rft.jtitle=Journal+of+acquired+immune+deficiency+syndromes+%281999%29&rft.au=Stephens%2C+Fay&rft.au=Gandhi%2C+Neel+R&rft.au=Brust%2C+James+C+M&rft.au=Mlisana%2C+Koleka&rft.date=2019-10-01&rft.issn=1944-7884&rft.eissn=1944-7884&rft.volume=82&rft.issue=2&rft.spage=124&rft_id=info:doi/10.1097%2FQAI.0000000000002120&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1944-7884&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1944-7884&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1944-7884&client=summon